Filing identity and reporting period
Important mismatch: The supplied filing is Health Sciences Acquisitions Corporation 2’s Form 10-K, not a filing by Orchestra Biomed Holdings, Inc. It covers the fiscal year ended December 31, 2021; the filing was signed March 31, 2022. Health Sciences Acquisitions Corporation 2 was a blank-check SPAC, not an operating healthcare company, and reported no operating revenue.
Financial results and position
| Metric | FY 2021 / Dec. 31, 2021 | Prior comparison |
|---|---|---|
| Revenue | None; no operating business | None |
| Net loss | $378,753 | $173,542 for May 25–Dec. 31, 2020, a shorter inception period |
| Operating expenses | $394,756: general and administrative $274,756; related-party administrative fee $120,000 | $179,986: $129,986 and $50,000, respectively |
| Trust investment income | $16,003 | $6,444 |
| Basic and diluted loss per share | $0.02 | $0.01 |
| Cash and working capital | Cash $1,754,460; working capital approximately $1.6 million | Cash $2,026,822 |
| Cash flow from operations | -$272,362 | -$258,508 |
| Trust account | $160,022,447 | $160,006,444 |
| Total assets / liabilities | $161,823,574 / $5,765,539 | $162,155,744 / $5,718,956 |
| Debt | No working-capital loans outstanding; $5.6 million deferred underwriting commission payable only if a business combination closes | Same deferred commission; no working-capital loans |
Margins are not meaningful for this pre-combination SPAC. The trust held funds in short-term U.S. Treasury securities; management considered interest-rate exposure immaterial.
Material changes and unusual items
- Net loss increased from $173,542 in the shorter 2020 inception period to $378,753 in 2021; administrative fees to the sponsor rose from $50,000 to $120,000.
- The company reported a material weakness in controls over accounting for complex financial instruments. Management said the weakness led to restatements of the 2020 balance sheet and financial statements and several 2020–2021 quarterly statements. Management reported additional analysis and ongoing remediation efforts.
- The independent auditor gave an unqualified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern because of the mandatory liquidation deadline.
Outlook, risks, and contingencies
- The company intended to seek a healthcare-focused business combination, but the filing says it had no specific transaction under consideration. It had until August 6, 2022 to complete a combination or face automatic winding up and liquidation.
- Management expected available working capital and borrowing capacity to cover needs through a business combination or one year from the filing, while acknowledging that the liquidation deadline raised substantial doubt about going concern. The financial statements contain no liquidation adjustments.
- Public shareholders could redeem shares in a business combination. If no combination closed, the initial distribution was expected to be $10 per public share, but creditor claims, insolvency proceedings, or delays could reduce or delay distributions. Sponsor protection against certain claims is limited and its ability to pay is not assured.
- The sponsor had agreed to purchase $25 million of company shares or equivalent target-company securities before, at, or after a business-combination closing. A separate $5.6 million deferred underwriting commission would be due only upon a completed combination.
- COVID-19 effects and the effects of Russia’s invasion of Ukraine and related sanctions were described as not readily determinable. No material litigation was reported.
- Potential conflicts include management’s other business affiliations and the sponsor’s interests. The filing also notes dilution from private warrants and the risk that those warrants expire worthless if no combination is completed.
Most important facts to verify
- Confirm issuer identity: this filing is for Health Sciences Acquisitions Corporation 2, not Orchestra Biomed Holdings, Inc.
- Verify the company’s business-combination and liquidation status after the August 6, 2022 deadline; this 10-K does not establish the eventual outcome.
- Review the restatement disclosures and any subsequent filings describing remediation of the material weakness in financial reporting controls.
- Check the trust balance, redemption terms, creditor claims, deferred underwriting commission, and sponsor’s $25 million purchase commitment against later transaction documents.
- Do not treat the 2020 comparison as a full-year comparison: it covers only May 25 through December 31, 2020.